• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Antisoma’s top management step down

Antisoma’s top management step down

March 2, 2011
CenterWatch Staff

The top management of Antisoma has stepped down, as the British cancer specialist cut its operations following the failure of its two leading drug candidates, Reuters reported.

The company's leukemia drug candidate AS1413 failed in a final-stage trial in January, delivering a second blow after the failure of a lung cancer drug, its biggest hope, in March 2010.

Chief Executive Glyn Edwards and finance director Eric Dodd both resigned, the company said, although Dodd will continue to advise the firm on strategic options, including a sale of the company.

January’s phase III ACCEDE trial of AS1413 (amonafide) in secondary acute myeloid leukemia failed to meet its primary endpoint, and consequently Antisoma decided to pull the plug on further development of the drug, leaving a substantial gap in its R&D pipeline, according to PharmaTimes. "This is hugely disappointing for patients, investigators, investors and employees," Edwards said.

In March 2010, ASA404 (vadimezan)--which was partnered with Swiss drug giant Novartis--failed in a late-stage clinical trial in patients with lung cancer, after showing that the drug offered minimal survival benefit. In November Novartis decided to terminate development of the drug, leaving Antisoma with much of its hopes pinned on the now failed AS1413. 

"The difficulties faced by Antisoma reflect a broader problem in cancer drug discovery, where phase II trials are too small and uncontrolled, and failures identifying the specific groups of patients on which to test drugs," said analyst Paul Cuddon at Peel Hunt, commenting on the failure, according to media reports. "Only when these problems are resolved do we see a future for small, focused cancer drug discovery companies."

Antisoma's pipeline now houses just three programs: AS1411, a novel aptamer drug with potential in blood cancers and solid tumours; DCAMs (dendritic cell autoimmune modulators), small-molecule kinase inhibitors in preclinical development with potential as oral therapeutics for autoimmune diseases; and PPMID, a new and highly targeted approach to cancer treatment in preclinical development in a collaboration with The Institute of Cancer Research.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing